

BEST AVAILABLE COPY

US Appln. No.-10/789,323
Filed: 2/27/04; Stapper et al
File: DEAV2003/0016US NP

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07D 513/04, A61K 31/54	A1	(11) International Publication Number: WO 97/26265 (43) International Publication Date: 24 July 1997 (24.07.97)
(21) International Application Number: PCT/DK97/00019		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 16 January 1997 (16.01.97)		
(30) Priority Data:		Published <i>With international search report.</i>
0041/96 17 January 1996 (17.01.96) 0250/96 5 March 1996 (05.03.96) 0251/96 5 March 1996 (05.03.96) 0252/96 5 March 1996 (05.03.96) 0253/96 5 March 1996 (05.03.96) 0256/96 5 March 1996 (05.03.96) 0259/96 5 March 1996 (05.03.96) 0903/96 27 August 1996 (27.08.96)	DK DK DK DK DK DK DK DK	
(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).		
(72) Inventors: NIELSEN, Flemming, Elmelund; Furesø Parkvej 46, DK-2830 Vinum (DK). HANSEN, Holger, Claus; Annexgårdsparken 43, DK-3500 Værløse (DK). HANSEN, John, Bondo; Langåsen 3, DK-4450 Jyderup (DK). TAG-MOSE, Tina, Møller, Farum Hovedgade 52, 204, DK-3520 Farum (DK).		
(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).		

(54) Title: FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE

(57) Abstract

1,2,4-thiadiazine and 1,4-thiazine derivatives represented by formula (I) wherein A, B, D, R¹, R², R³ and R⁴ are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russia Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TITLE

Fused 1,2,4-Thiadiazine and Fused 1,4-Thiazine Derivatives, their Preparation and Use

5

FIELD OF THE INVENTION

The present invention relates to fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, to methods for their preparation, to compositions comprising the compounds, to the use of these 10 compounds as medicaments and their use in therapy e.g. in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

BACKGROUND OF THE INVENTION

15

Potassium channels play an important role in membrane potential. Among the different types of potassium channels are the ATP-sensitive (K_{ATP}) channels which are regulated by changes in the intracellular concentration of adenosine triphosphate. The K_{ATP} -channels have been found in cells from various tissues such as cardiac cells, pancreatic-cells, skeletal muscles, smooth muscles, 20 central neurons and adenohypophysis cells. The channels have been associated with diverse cellular functions for example hormone secretion (insulin from pancreatic beta-cells, growth hormone and prolactin from adenohypophysis cells), vasodilation (in smooth muscle cells), cardiac action potential duration, neurotransmitter release in the central nervous system.

25

Modulators of the K_{ATP} -channels have been found to be of importance for the treatment of various diseases. Certain sulphonylureas which have been used for the treatment of non-insulin-dependent diabetes mellitus

30

act by stimulating insulin release through an inhibition of the K_{ATP} -channels on pancreatic beta-cells.

The potassium channel openers, which comprise a heterogeneous group of compounds, have been found to be able to relax vascular smooth muscles and have therefore been used for the treatment of hypertension.

35

In addition, potassium channel openers can be used as bronchodilators in the treatment of asthma and various other diseases.

Furthermore, potassium channel openers have been shown to promote hairgrowth, and have been used for the treatment of baldness.

Potassium channel openers are also able to relax urinary bladder smooth muscle and therefore, can be used for the treatment of urinary incontinence. Potassium channel openers which relax smooth muscle of the uterus can be used for treatment of premature labor.

By acting on potassium channels of the central nervous system these compounds can be used for treatment of various neurological and psychiatric diseases such as Alzheimer, epilepsy and cerebral ischemia.

Recently, it has been shown that Diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide) and certain 3-(alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide derivatives inhibit insulin release by an activation of K_{ATP} -channels on pancreatic beta-cells (Pirotte B. et al. *Biochem. Pharmacol.*, 47, 1381-1386 (1994); Pirotte B. et al., *J. Med. Chem.*, 36, 3211-3213 (1993)).

Diazoxide has furthermore been shown to delay the onset of diabetes in BB-rats (Vlahos WD et al. *Metabolism* 40, 39-46 (1991). In obese zucker rats diazoxide has been shown to decrease insulin secretion and increase insulin receptor binding and consequently improve glucose tolerance and decrease weight gain (Alemzadeh R. et al. *Endocrinol.* 133, 705-712, 1983). It is expected that such compounds can be used for treatment of diseases characterised by an overproduction of insulin and for the treatment and prevention of diabetes.

EP 618 209 discloses a class of pyridothiadiazine derivatives having an alkyl or an alkylamino group in position 3 of the thiadiazine ring. These compounds are claimed to be agonists at the AMPA-glutamate receptor.


In *J. Med. Chem.* 1980, 23, 575-577 the synthesis of 4(5)-amino-and formylaminoimidazo-5(4) carboxamide and their properties as agents of chemotherapeutic value are described. Especially, the compounds 3-aminoimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide and N-benzoylaminoimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide are shown.

DESCRIPTION OF THE INVENTION

The present invention relates to fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives of the ge-

35 neral formula I:

5



wherein

B represents $>\text{NR}^5$ or $>\text{CR}^5\text{R}^6$, wherein R^5 and R^6 independently are hydrogen; hydroxy; C_{1-6} -alkoxy; or C_{1-6} -alkyl, C_{3-6} -cycloalkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen; or R^5 and R^6 together represent one of the bonds in a double bond between the atoms 2 and 3 of formula I;

D represents $-\text{S}(=\text{O})_2-$ or $-\text{S}(=\text{O})-$; or
15

D-B represents $-\text{S}(=\text{O})(\text{R}^7)=\text{N}-$

wherein R^7 is C_{1-6} -alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with halogen, hydroxy, C_{1-6} -alkoxy, aryloxy, arylalkoxy, nitro, amino, C_{1-6} -monoalkyl- or dialkylamino, cyano, acyl, or 20 C_{1-6} -alkoxycarbonyl;

R^1 is hydrogen; hydroxy; C_{1-6} -alkoxy; or C_{1-6} -alkyl, C_{3-6} -cycloalkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen and R^4 is hydrogen or R^4 together with R^5 represent one of the bonds in a double bond between the atoms 2 and 3 of formula I; or R^1 together with R^4 25 represent one of the bonds in a double bond between the atoms 3 and 4 of formula I;

R^2 is hydrogen; hydroxy; C_{1-6} -alkoxy; or C_{1-6} -alkyl, C_{3-6} -cycloalkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen;

30 R^3 is R^8 ; $-\text{OR}^8$; $-\text{C}(=\text{X})\text{R}^8$; $-\text{NR}^8\text{R}^9$; bicycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl optionally mono- or polysubstituted with halogen, hydroxy, C_{1-6} -alkoxy, aryloxy, arylalkoxy, nitro, amino, C_{1-6} -monoalkyl- or dialkylamino, cyano, oxo, acyl or C_{1-6} -alkoxycarbonyl; or aryl substituted with C_{1-6} -alkyl;

35 wherein R^8 is hydrogen; C_{3-6} -cycloalkyl or $(\text{C}_{3-6}$ -cycloalkyl) C_{1-6} -alkyl, the C_{3-6} -cycloalkyl group optionally being mono- or polysubstituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms; or straight or branched C_{1-18} -alkyl optionally mono- or polysubstituted with halogen, hydroxy, C_{1-6} -alkoxy,

C_{1-6} -alkylthio, C_{3-6} -cycloalkyl, aryl, aryloxy, arylalkoxy, nitro, amino, C_{1-6} -monoalkyl- or dialkylamino, cyano, oxo, formyl, acyl, carboxy, C_{1-6} -alkoxycarbonyl, or carbamoyl;


X is O or S;

5

R^9 is hydrogen; C_{1-6} -alkyl; C_{2-6} -alkenyl; C_{3-6} -cycloalkyl optionally mono- or polysubstituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy; or

10 R^8 and R^9 together with the nitrogen atom form a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted with halogen, C_{1-6} -alkyl, hydroxy, C_{1-6} -alkoxy, C_{1-6} -alkoxy- C_{1-6} -alkyl, nitro, amino, cyano, trifluoromethyl, C_{1-6} -monoalkyl- or dialkylamino, oxo; or

15 R^3 is



20 wherein n,m,p independently are 0,1,2,3 and R^{10} is hydrogen; hydroxy; C_{1-6} -alkoxy; C_{3-6} -cycloalkyl optionally mono- or polysubstituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy; C_{1-6} -alkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen; or

25 R^2 and R^3 together with the nitrogen atom forms a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted with halogen, C_{1-6} -alkyl, hydroxy, C_{1-6} -alkoxy, C_{1-6} -alkoxy- C_{1-6} -alkyl, nitro, amino, cyano, trifluoromethyl, C_{1-6} -monoalkyl- or dialkylamino or oxo;

30 A together with carbon atoms 5 and 6 of formula I represents a 5 or 6 membered heterocyclic system comprising one or more nitrogen-, oxygen- or sulfur atoms, the heterocyclic systems optionally being mono- or polysubstituted with halogen; C_{1-12} -alkyl; C_{3-6} -cycloalkyl; hydroxy; C_{1-6} -alkoxy; C_{1-6} -alkoxy- C_{1-6} -alkyl; nitro; amino; cyano; cyanomethyl; perhalomethyl; C_{1-6} -monoalkyl- or dialkylamino; sulfamoyl; C_{1-6} -alkylthio; C_{1-6} -alkylsulfonyl; C_{1-6} -alkylsulfanyl; C_{1-6} -alkylcarbonylamino; arylothio, arylsulfanyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy; C_{1-6} -alkoxycarbonyl; C_{1-6} -alkoxycarbonyl- C_{1-6} -alkyl; carbamyl; carbamyl-methyl; C_{1-6} -monoalkyl- or dialkylaminocarbonyl; C_{1-6} -monoalkyl- or dialkylaminothiocarbonyl; ureido; C_{1-6} -monoalkyl- or dialkylaminocarbonylamino, thioureido; C_{1-6}

- monoalkyl- or dialkylaminothiocarbonyl-amino; C₁₋₆-monoalkyl- or dialkylaminosulfonyl; carboxy; carboxy-C₁₋₆-alkyl; acyl; aryl, arylalkyl, aryloxy, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)-C₁₋₆-alkyl the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl;

provided that A together with carbon atoms 5 and 6 of formula I do not form a pyridine ring and that the following compounds 3-amino-2,5-dihydroimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide and 3-benzoylamino-2,5-dihydroimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide are not included;

or a salt thereof with a pharmaceutically acceptable acid or base.

Within its scope the invention includes all optical isomers of compounds of formula I, some of which are optically active, and also their mixtures including racemic mixture thereof.

The scope of the invention also includes all tautomeric forms of the compounds of formula I.

The salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts or optionally alkylated ammonium salts, such as hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, trifluoroacetic, trichloroacetic, oxalic, maleic, pyruvic, malonic, succinic, citric, tartaric, fumaric, mandelic, benzoic, cinnamic, methanesulfonic, ethane sulfonic, picric and the like, and include acids related to the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) and incorporated herein by reference, or lithium, sodium, potassium, magnesium and the like.

The term "C₁₋₆-alkoxy" as used herein, alone or in combination, refers to a straight or branched monovalent substituent comprising a C₁₋₆-alkyl group linked through an ether oxygen having its free valence bond from the ether oxygen and having 1 to 6 carbon atoms e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy.

The term "C₁₋₆-alkylthio" as used herein, alone or in combination, refers to a straight or branched monovalent substituent comprising a lower alkyl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom and having 1 to 6 carbon atoms e.g. methylthio, ethylthio, propylthio, butylthio, pentylthio.

The term "C₂₋₆-alkenyl" as used herein refers to an unsaturated hydrocarbon chain having 2-6 carbon

atoms and one double bond such as e.g. vinyl, 1-propenyl, allyl, isopropenyl, n-but enyl, n-pentenyl and n-hexenyl.

The term "C₃₋₆-cycloalkyl" as used herein refers to a radical of a saturated cyclic hydrocarbon with the indicated number of carbons such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

5

The term "C₂₋₆-alkynyl" as used herein refers to unsaturated hydrocarbons which contain triple bonds, such as e.g. -C≡CH, -C≡CCH₃, -CH₂C≡CH, -CH₂CH₂C≡CH, -CH(CH₃)C≡CH, and the like.

10 The term "C₁₋₆-alkoxy-C₁₋₆-alkyl" as used herein refers to a group of 2-12 carbon atoms interrupted by an O such as e.g. CH₂-O-CH₃, CH₂-O-CH₂-CH₃, CH₂-O-CH(CH₃)₂ and the like.

The term "halogen" means fluorine, chlorine, bromine or iodine.

15 The term "perhalomethyl" means trifluoromethyl, trichloromethyl, tribromomethyl or triiodomethyl.

The terms "C₁₋₆-alkyl", "C₁₋₁₂-alkyl" and "C₁₋₁₈-alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms such as e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 4-methylpentyl, neopentyl, n-hexyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1,2,2-trimethylpropyl and the like. The term "C₁₋₁₈-alkyl" as used herein also includes secondary C₃₋₆-alkyl and tertiary C₄₋₆-alkyl.

25 The term "C₁₋₆-monoalkylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms such as e.g. methylamino, ethylamino, propylamino, n-butylamino, sec-butylamino, isobutylamino, tert-butylamino, n-pentylamino, 2-methylbutylamino, n-hexylamino, 4-methylpentylamino, neopentylamino, n-hexylamino, 2,2-dimethylpropylamino and the like.

30 The term "C₁₋₆-dialkylamino" as used herein refers to an amino group wherein the two hydrogen atoms independently are substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms; such as dimethylamino, N-ethyl-N-methylamino, diethylamino, dipropylamino, N-(n-butyl)-N-methylamino, di(n-pentyl)amino, and the like.

35 The term "acyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-alkyl group linked through a carbonyl group; such as e.g. acetyl, propionyl, butyryl, isobutyryl, pivaloyl, valeryl, and the like.

- The term "C₁₋₆-alkoxycarbonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-alkoxy group linked through a carbonyl group; such as e.g. methoxycarbonyl, carbethoxy, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, 3-methylbutoxycarbonyl, n-hexoxycarbonyl and the like.

5 The term "3-12 membered mono- or bicyclic system" as used herein refers to a monovalent substituent of formula -NR²R³ or -NR⁸R⁹ where R² and R³, or R⁸ and R⁹ together with the nitrogen atom form a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms 10 may be exchanged with nitrogen, oxygen or sulfur, such as 1-pyrrolidyl, piperidino, morpholino, thiomorpholino, 4-methylpiperazin-1-yl, 7-azabicyclo[2.2.1]heptan-7-yl, tropanyl and the like.

15 The term "3-6 membered saturated ring system" as used herein refers to a monovalent substituent comprising a monocyclic saturated system containing one or more hetero atoms selected from nitrogen, oxygen and sulfur and having 3-6 members and having its free valence from a carbon atom, e.g. 2-pyrrolidyl, 4-piperidyl, 3-morpholiny, 1,4-dioxan-2-yl, 5-oxazolidinyl, 4-isoxazolidinyl or 2-thiomorpholiny.

20 The term "bicycloalkyl" as used herein refers to a monovalent substituent comprising a bicyclic structure made of 6-12 carbon atoms such as e.g. 2-norbornyl, 7-norbornyl, 2-bicyclo[2.2.2]octyl and 9-bicyclo[3.3.1]nonanyl.

The term "aryl" as used herein refers to phenyl, 1-naphthyl or 2-naphthyl.

25 The term "heteroaryl" as used herein, alone or in combination, refers to a monovalent substituent comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g. pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoazazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine.

30 The term "arylalkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic carbohydride; such as benzyl, phenethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-(1-naphthyl)ethyl and the like.

35 The term "aryloxy" as used herein refers to phenoxy, 1-naphthyoxy or 2-naphthyoxy.

The term "arylalkoxy" as used herein refers to a C₁₋₆-alkoxy group substituted with an aromatic carbohydride, such as benzyloxy, phenethoxy, 3-phenylpropoxy, 1-naphthylmethoxy, 2-(1-naphtyl)ethoxy and the like.

- 5 The term "heteroarylalkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with a heteroaryl group; such as (2-furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl-1-(2-pyrimidyl)ethyl and the like.
- 10 The term "C₁₋₆-alkylsulfonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-alkyl group linked through a sulfonyl group such as e.g. methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, sec-butylsulfonyl, isobutylsulfonyl, tert-butylsulfonyl, n-pentylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, n-hexylsulfonyl, 4-methylpentylsulfonyl, neopentylsulfonyl, n-hexylsulfonyl and 2,2-dimethylpropylsulfonyl.
- 15 The term "C₁₋₆-monoalkylaminosulfonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-monoalkylamino group linked through a sulfonyl group such as e.g. methylaminosulfonyl, ethylaminosulfonyl, n-propylaminosulfonyl, isopropylaminosulfonyl, n-butylaminosulfonyl, sec-butylaminosulfonyl, isobutylaminosulfonyl, tert-butylaminosulfonyl, n-pentylaminosulfonyl, 2-methylbutylaminosulfonyl, 3-methylbutylaminosulfonyl, n-hexylaminosulfonyl, 4-methylpentylaminosulfonyl, neopentylaminosulfonyl, n-hexylaminosulfonyl and 2,2-dimethylpropylaminosulfonyl.
- 20 The term "C₁₋₆-dialkylaminosulfonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-dialkylamino group linked through a sulfonyl group such as dimethylaminosulfonyl, N-ethyl-N-methylaminosulfonyl, diethylaminosulfonyl, dipropylaminosulfonyl, N-(n-butyl)-N-methylaminosulfonyl, di(n-pentyl)aminosulfonyl, and the like.
- 25 The term "C₁₋₆-alkylsulfinyl" as used herein refers to a monovalent substituent comprising a straight or branched C₁₋₆-alkyl group linked through a sulfinyl group (-S(=O)-); such as e.g. methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, butylsulfinyl, pentylsulfinyl, and the like.
- 30 The term "C₁₋₆-alkylcarbonylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with an acyl group, such as e.g. acetamido, propionamido, isopropylcarbonylamino, and the like.
- 35 The term "(C₃₋₆-cycloalkyl)C₁₋₆-alkyl" as used herein, alone or in combination, refers to a straight or

branched, saturated hydrocarbon chain having 1 to 6 carbon atoms and being monosubstituted with a C₃₋₆-cycloalkyl group, the cycloalkyl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; such as e.g. cyclopropylmethyl, (1-methylcyclopropyl)methyl, 1-(cyclopropyl)ethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.

5

The term "arylthio" as used herein, alone or in combination, refers to an aryl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; e.g. phenylthio, (4-methylphenyl)-thio, (2-chlorophenyl)thio, and the like.

10

The term "arylsulfinyl" as used herein refers to an aryl group linked through a sulfinyl group (-S(=O)-), the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; such as e.g. phenylsulfinyl, (4-chlorophenyl)sulfinyl, and the like.

15

The term "arylsulfonyl" as used herein refers to an aryl group linked through a sulfonyl group, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; such as e.g. phenylsulfonyl, tosyl, and the like.

20

The term "C₁₋₆-monoalkylaminocarbonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-monoalkylamino group linked through a carbonyl group such as e.g. methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, n-butylaminocarbonyl, sec-butylaminocarbonyl, isobutylaminocarbonyl, tert-butylaminocarbonyl, n-pentylaminocarbonyl, 2-methylbutylaminocarbonyl, 3-methylbutylaminocarbonyl, n-hexylaminocarbonyl, 4-methylpentylaminocarbonyl, neopentylaminocarbonyl, n-hexylaminocarbonyl and 2-2-dimethylpropylaminocarbonyl.

25

The term "C₁₋₆-dialkylaminocarbonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-dialkylamino group linked through a carbonyl group such as dimethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, N-(n-butyl)-N-methylaminocarbonyl, di(n-pentyl)aminocarbonyl, and the like.

30

The term "C₁₋₆-monoalkylaminocarbonylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with a C₁₋₆-monoalkylaminocarbonyl group, e.g. methylaminocarbonylamino, ethylamino-carbonylamino, n-propylaminocarbonylamino, isopropylaminocarbonylamino, n-butylaminocarbonylamino, sec-butylaminocarbonylamino, iso-butylaminocarbonylamino, tert-butylaminocarbonylamino, and 2-methylbutylaminocarbonylamino.

35

The term "C₁₋₆-dialkylaminocarbonylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with a C₁₋₆-dialkylaminocarbonyl group, such as dimethylaminocarbonylamino, N-ethyl-N-methylaminocarbonylamino, diethylaminocarbonylamino, dipropylaminocarbonylamino, N-(n-butyl)-N-methylaminocarbonylamino, di(n-pentyl)aminocarbonylamino, and the like.

The term "5- or 6-membered heterocyclic system" as used herein refers to: a monocyclic unsaturated or saturated system containing one, two or three hetero atoms selected from nitrogen, oxygen and sulfur and having 5 members, e.g. pyrrole, furan, thiophene, pyrrolidine, dihydrofuran,


10 dihydrothiophene, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, thiazole, isoxazole, isothiazole, 1,2,3-oxadiazole, furazan, 1,2,3-triazole, 1,2,3-thiadiazole or 2,1,3-thiadiazole; an aromatic monocyclic system containing two or more nitrogen atoms and having 6 members, e.g. pyrazine, pyrimidine, pyridazine, 1,2,4-triazine, 1,2,3-triazine or tetrazine; a non-aromatic monocyclic system containing one or more hetero atoms selected from nitrogen, oxygen and sulfur and having 6 members, e.g. pyran, thiopyran, piperidine, dioxane, oxazine, isoxazine, dithiane, oxathine, thiazine, 15 piperazine, thiadiazine, dithiazine or oxadiazine.

The term "5- or 6-membered nitrogen containing ring" as used herein refers to a monovalent substituent comprising a monocyclic unsaturated or saturated system containing one or more nitrogen atoms and having 5 or 6 members, e.g. pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, pyrrolyl, 2H-pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, morpholino, thiomorpholino, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, 1,3-dioxolanyl and 1,4-dioxolanyl.

25 Within its scope the invention includes all optical isomers of compounds of formula I, some of which are optically active, and also their mixtures including racemic mixture thereof.

In a preferred embodiment of the invention the general formula of formula I is selected from

30



35

wherein

R¹ and R⁵ independently are hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl

11

or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or

R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I and R¹ is as defined above; or

5


R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I and R⁵ is as defined above;

D represents -S(=O)₂- or -S(=O)-.

10

In another preferred embodiment of the invention the general formula of formula I is selected from

15



wherein

R¹ is hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or

20

R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I;


D represents -S(=O)R⁷=

25

wherein R⁷ is C₁₋₆-alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, acyl or C₁₋₆-alkoxycarbonyl.

30 In another preferred embodiment of the invention the general formula of formula I is selected from

5



wherein

R¹, R⁵ and R⁶ independently are hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-

10 alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or

R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I and R¹ and R⁶ are as defined above; or

15 R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I and R⁵ and R⁶ are as defined above;

D represents -S(=O)₂⁻ or S(=O).

20 Preferably, the general formula of formula I is (Ia).

In another preferred embodiment of the invention D is -S(=O)₂⁻.

25 In another preferred embodiment of the invention R¹ is selected from hydrogen, C₁₋₆-alkyl, C₃₋₆-cycloalkyl or C₂₋₆-alkenyl. Preferably R¹ is hydrogen or C₁₋₆-alkyl.

In another preferred embodiment of the invention R¹ together with R⁴ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I.

30 In another preferred embodiment of the invention R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I.

In another preferred embodiment of the invention R² is selected from hydrogen, hydroxy, C₁₋₆-alkyl, C₃₋₆-cycloalkyl or C₂₋₆-alkenyl. Preferably R² is hydrogen or C₁₋₆-alkyl.

35 In another preferred embodiment of the invention R³ is selected from R⁸, -OR⁸, -NR⁸R⁹ or aryl, the aryl group optionally being substituted with C₁₋₆-alkyl; wherein R⁸ is hydrogen; C₃₋₆-cycloalkyl; (C₃₋₆-

- cycloalkyl)C₁₋₆-alkyl; a 3-6-membered saturated ring system comprising one, two or three nitrogen-, oxygen- or sulfur atoms; or straight or branched C₁₋₁₂-alkyl optionally substituted with halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkyl or aryl; R⁹ is hydrogen, C₁₋₆-alkyl or C₃₋₆-cycloalkyl; or R⁸ and R⁹ together with the nitrogen atom form a 4 - 6 membered ring, preferably 1-pyrrolidyl, 5 piperidine or morpholino.
- In yet another preferred embodiment of the invention R³ is selected from secondary C₃₋₆-alkyl, tertiary C₄₋₆-alkyl, C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)methyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy. Preferably R³ is selected from isopropyl, 1-methylpropyl, 2-methylpropyl, 10 tert-butyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1,2,2-trimethylpropyl, 2,3-dimethylbutyl, 1-ethylpropyl, 1-ethyl-2-methylpropyl, 1-ethyl-2,2-dimethylpropyl, 2,3,3-trimethylbutyl, 2-methylbutyl, 1,5-dimethylhexyl, 3-methylbutyl, 3-methylhexyl, cyclopropyl, 1-methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, 1-(cyclopropyl)ethyl cyclobutylmethyl, cyclopentylmethyl or cyclohexylmethyl.
- 15 In a further preferred embodiment of the invention R² and R³ together with the nitrogen atom forms a six membered ring, optionally substituted in the 2-position with a C₁₋₆-alkyl group, preferably selected from methyl, ethyl or isopropyl. Preferably the six membered ring is a piperidine, piperazine, morpholine or thiomorpholine ring.
- 20 In another preferred embodiment of the invention R⁷ is selected from C₁₋₆-alkyl, phenyl or pyridyl.
- In another preferred embodiment of the invention A forms together with carbon atoms 5 and 6 of formula I a 5 membered heterocyclic system containing one hetero atom selected from nitrogen and sulfur, a 5 membered heterocyclic system containing two hetero atoms selected from nitrogen, 25 oxygen and sulfur, a 6 membered aromatic heterocyclic system containing two or three nitrogen atoms, a 6 membered non-aromatic heterocyclic system containing one or two hetero atoms selected from nitrogen, oxygen and sulfur; the heterocyclic systems optionally being mono- or disubstituted with halogen; C₁₋₁₂-alkyl; C₃₋₆-cycloalkyl; cyano; cyanomethyl; perhalomethyl; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamylmethyl; carboxy-C₁₋₆-alkyl; aryloxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)C₁₋₆-alkyl, the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; acyl; or a 5 - 30 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl.
- 35 Preferably, A forms together with carbon atoms 5 and 6 a thieno[3,2-e]- or pyrrolo[3,2-e]-ring, thiophene, imidazole, thiazole, pyrazole, isoaxazole or isothiazole, a pyrazino[2,3-e]-, a pyrimido[4,5-e]-, a pyrimido[5,4-e]-, a pyridazino[4,5-e]- or a pyridazino[4,3-e]-ring, thiopyran, piperidine, dioxane,

oxazine or dithiane.

Preferred compounds of the invention are:

- 5 6-Chloro-3-(1,2-dimethylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-ethylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 10 (R)-6-Chloro-3-(1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Allylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 15 6-Chloro-3-cyclopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-hexylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-tetradecylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
- 20 6-Chloro-3-methylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Benzylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 25 6-Chloro-3-octylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-isobutylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-(4-phenylbutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 30 6-Chloro-3-(1,5-dimethylhexyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-propylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 35 (R)-6-Chloro-3-(2-hydroxy-1-methylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- (S)-6-Chloro-3-(2-hydroxy-1-methylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

- (R)-3-sec-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 5 3-Isopropylamino-7-methyl-4,7-dihydro-pyrazolo[4,3-e][1,2,4]thiadiazine 1,1-dioxide;
- (S)-6-Chloro-3-(1,2-dimethylpropylamino)-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 10 (R)-6-Chloro-3-(1,2-dimethylpropylamino)-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Isopropylamino-6-methyl-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Hexylamino-6-methyl-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;
- 15 6-methyl-3-octylamino-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-isopropylamino-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;
- 20 6-Dimethylamino-3-isopropylamino-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Bromo-3-isopropylamino-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Isopropylamino-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;
- 25 6-Ethythio-3-isopropylamino-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Isopropylamino-6-methoxy-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;
- 30 3-Isopropylamino-4H-thiazolo[5,4-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Bromo-3-isopropylamino-4H-thiazolo[5,4-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-5-bromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 35 5,6-Dibromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

- 6-Benzenesulfonyl-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-isopropylamino-5-nitro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 5 3-Isopropylamino-5-methyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Isopropylamino-5-phenyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Isopropylamino-6-phenyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 10 6-Cyano-3-isopropylamino-5-methyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Cyano-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 15 3-Isopropylamino-5,6-dimethyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 5-Cyclopropyl-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Isopropylamino-5-(4-methoxyphenyl)-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 20 5-Cyclohexyl-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 5-Ethyl-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 25 6-Chloro-3-(3-methylbutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 6-Chloro-3-(3-methylhexyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
- 3-Isopropylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;
- 30 3-Isopropylamino-7-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;
- 7-Cyano-3-isopropylamino-6-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;
- 35 3-Isopropylamino-7-ethyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;
- 7-Cyano-3-isopropylamino-6-methylthio-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;

7-Cyano-3-isopropylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;

3-Isopropylamino-4H-thieno[3,4-e]-1,2,4-thiadiazine 1,1-dioxide;

5

5,7-Dichloro-3-isopropylamino-4H-thieno[3,4-e]-1,2,4-thiadiazine 1,1-dioxide;

3-Cyclopropylamino-7-methyl-4,7-dihydro-pyrazolo[4,3-e][1,2,4]thiadiazine 1,1-dioxide;

10 3-Hexylamino-7-methyl-4,7-dihydro-pyrazolo[4,3-e][1,2,4]thiadiazine 1,1-dioxide;

7-Methyl-3-octylamino-4,7-dihydro-pyrazolo[4,3-e][1,2,4]thiadiazine 1,1-dioxide;

2,5-Dihydro-3-isopropylamino-imidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

15

2,5-Dihydro-3-isopropylamino-5-methyl-imidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

2,7-Dihydro-3-isopropylamino-7-methyl-imidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

20 3-Isopropylamino-4H-pyrazino[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;

3-Isopropylamino-5,7-dimethyl-6,8-dioxo-5,6,7,8-tetrahydro-4H-pyrimido[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

25 3-(1,2-Dimethylpropyl)amino-2H-pyrazino[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;

3-(1-Methylpropyl)amino-2H-pyrazino[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;

3-(2-Methylpropyl)amino-2H-pyrazino[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;

30

3-Butylamino-2H-pyrazino[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;

3-Propylamino-2H-pyrazino[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;

35

3-(1,2,2-Trimethylpropyl)amino-2H-pyrazino[2,3-e]-1,2,4-thiadiazine 1,1-dioxide;

6-Chloro-3-(1,2-dimethylpropyl)amino-2H-thieno[3,2-e]-1,2,4-thiadiazine 1,1 dioxide;

6-Chloro-3-(1-methylpropyl)amino-2H-thieno[3,2-e]-1,2,4-thiadiazine 1,1 dioxide;

6-Chloro-3-(2-methylpropyl)amino-2H-thieno[3,2-e]-1,2,4-thiadiazine 1,1 dioxide;

5

3-Butylamino-6-chloro-2H-thieno[3,2-e]-1,2,4-thiadiazine 1,1 dioxide;

6-Chloro-3-propylamino-2H-thieno[3,2-e]-1,2,4-thiadiazine 1,1 dioxide;

10 6-Chloro-3-(1,2,2-trimethylpropyl)amino-2H-thieno[3,2-e]-1,2,4-thiadiazine 1,1 dioxide;

3-(1,2-Dimethylpropyl)amino-2H-thieno[2,3-e]-1,2,4-thiadiazine 1,1 dioxide;

3-(1-Methylpropyl)amino-2H-thieno[2,3-e]-1,2,4-thiadiazine 1,1 dioxide;

15

3-(2-Methylpropyl)amino-2H-thieno[2,3-e]-1,2,4-thiadiazine 1,1 dioxide;

3-Butylamino-2H-thieno[2,3-e]-1,2,4-thiadiazine 1,1 dioxide;

20

3-Propylamino-2H-thieno[2,3-e]-1,2,4-thiadiazine 1,1 dioxide;

3-(1,2,2-Trimethylpropyl)amino-2H-thieno[2,3-e]-1,2,4-thiadiazine 1,1 dioxide;

3-(1,2-Dimethylpropyl)amino-2H-pyrimido[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

25

3-(1-Methylpropyl)amino-2H-pyrimido[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

3-(2-Methylpropyl)amino-2H-pyrimido[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

30

3-Butylamino-2H-pyrimido[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

3-Propylamino-2H-pyrimido[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

3-(1,2,2-Trimethylpropyl)amino-2H-pyrimido[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

35

3-(1,2-Dimethylpropyl)amino-2H-pyridazino[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

3-(1-Methylpropyl)amino-2H-pyridazino[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

3-(2-Methylpropyl)amino-2H-pyridazino[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

5 3-Butylamino-2H-pyridazino[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

3-Propylamino-2H-pyridazino[4,5-e]-1,2,4-thiadiazine 1,1-dioxide;

3-(1,2,2-Trimethylpropyl)amino-2H-pyridazino[4,5-e]-1,2,4-thiadiazine 1,1-dioxide.

10

The compounds of the present invention interact with the potassium channels and hence act as openers or blockers of the ATP-regulated potassium channels, which make them useful in the treatment of various diseases of the cardiovascular system, e.g. cerebral ischemia, hypertension, ischemic heart diseases, angina pectoris and coronary heart diseases; the pulmonary system; the gastrointestinal system; the central nervous system and the endocrinological system.

15

Since some K_{ATP} -openers are able to antagonize vasospasms in basilar or cerebral arteries the compounds of the present invention can be used for the treatment of vasospastic disorders such as subarachnoid haemorrhage and migraine.

20

Potassium channel openers hyperpolarizes neurons and inhibit neurotransmitter release and it is expected that the present compounds can be used for the treatment of various diseases of the central nervous system, e.g. epilepsy, ischemia and neurodegenerative diseases, and for the management of pain.

25

By acting on potassium channels of the central nervous system the compounds of the present invention can be used for treatment of various neurological and psychiatric diseases such as Alzheimer, epilepsy and cerebral ischemia.

30

The compounds of the present invention may also be used for the treatment of diseases associated with decreased skeletal muscle blood flow such as Reynauds disease and intermittent claudication.

Further, the compounds of the invention may be used for the treatment of chronic airway diseases, including asthma, and for treatment of detrusor muscle instability secondary to bladder outflow

35

obstruction and therefore for kidney stones by aiding their passage along the ureter. Potassium channel openers also relax urinary bladder smooth muscle, thus, the compounds of the present invention can be used for the treatment of urinary incontinence.

The present compounds could also be used for treatment of conditions associated with disturbances in gastrointestinal mobility such as irritable bowel syndrome. Additionally these compounds can be used for the treatment of premature labor and dysmenorrhea.

5

Further, potassium channel openers promote hairgrowth, therefore, the compounds of the present invention can be used for the treatment of baldness.

- In diseases such as nesidioblastosis and insulinoma in which a hypersecretion of insulin causes
10 severe hypoglycemia the compounds of the present invention can be used to reduce insulin secretion.
In obesity hyperinsulinemia and insulin resistance is very frequently encountered. This condition could lead to the development of noninsulin dependent diabetes (NIDDM). It is expected that potassium
channel openers and hence the compounds of the present invention can be used for contracting the
hyperinsulinemia and thereby prevent diabetes and reduce obesity. In overt NIDDM treatment of
15 hyperinsulinemia with potassium channel openers, and hence the present compounds, can be of
benefit in restoring glucose sensitivity and normal insulin secretions.

- In early cases of insulin dependent diabetes (IDDM) or in prediabetic cases, potassium channel
openers and hence the present compounds can be used to induce betacell rest which may prevent
20 the progression of the autoimmune disease.

- Compounds of the present invention which act as blockers of K_{ATP} -channels can be used for the
treatment of NIDDM.
25 Preferably, the compounds of the present invention may be used for treatment or prevention of diseases of the endocrinological system such as hyperinsulinaemia and diabetes.

- Accordingly, in another aspect the invention relates to a compound of the general formula I or a
pharmaceutically acceptable acid addition salt thereof for use as a therapeutically acceptable
30 substance, preferably for use as a therapeutically acceptable substance in the treatment of
hyperinsulinaemia and treatment or prevention of diabetes.

- Furthermore, the invention also relates to the use of the inventive compounds of formula I as
medicaments useful for treating hyperinsulinaemia and treating or preventing diabetes.
35 In yet another aspect, the present invention relates to methods of preparing the above mentioned
compounds. The methods comprises:

a) reacting a compound of formula II:

5



10

wherein A, B, D, R¹ and R⁴ are as defined above and Z is a leaving group such as alkoxy, alkylthio, halogen, preferentially chloro, bromo, iodo, trimethylamino, or methylsulfonyl with a compound of formula III:

15



wherein R² and R³ are defined above to form a compound of the general formula I using procedures described by e.g. T. H. Cronon et al., *J. Med. Chem.* 11, 136 (1968); L. Raffa et al., *Farmaco Ed. Sci.* 29, 411 (1974); B. Pirotte et al., *J. Med. Chem.* 36, 3211 (1993).

Another method comprises:

25

b) reacting a compound of formula IV:

30



35

wherein R¹ is hydrogen and A, B, D and X are as defined above, or B is NH and R¹, A, D and X are as defined above, with the compound of formula III, or a suitable salt thereof in the presence of P₂O₅

and a high boiling tertiary amine or a suitable salt therof using a procedure described by Jensen K.G. and Pedersen E.B., *Chem. Scr.*, **20**, 248-250 (1988) and Andersen L., Nielsen F.E. and Pedersen E.B., *Chem. Scr.*, **29**, 45-49 (1989), to form a compound of the general formula I.

5 c) reacting a compound of the formula IV:



wherein R¹ is hydrogen and A, B, D and X are as defined above or B is NH and R¹, A, D and X are as defined above, with a compound of the formula III, or a suitable salt thereof in the presence of titanium tetrachloride and a solvent with which it may form a complex, like e.g. tetrahydrofuran, or a mixture of toluene and anisole, according to the methods described in R.I. Fryer, J.V. Earley, G.F. Field, W. Zally, and L.H. Stembach, *J.Org.Chem.* **34**, 1143-1145 (1969); J.B. Press et al., *J.Med.Chem.* **22**, 725-731 (1979); or G. Roma et al. *Eur.J.Med.Chem.* **26**, 489-496 (1991), to form a compound of the general formula I.

d) reacting a compound of formula V




wherein R¹ and A are as defined above, with a compound of formula VI

$$\text{R}^3\text{NCO} \quad (\text{VI})$$

wherein R³ is as defined above using the method described by Chem J.W. et al., *J. Heterocycl. Chem.*, 27, 1909-1915 (1990), to form a compound of the general formula I wherein D is SO₂, B is >NR⁵, R² is H, and R⁴ and R⁵ together form a bond.

e) reacting a compound of the formula V

5



(V)

wherein R¹ and A are as defined above, with a compound of formula VII

10




(VII)

wherein R³ is as defined above using the method described by Chem J.W. et al., *J. Heterocycl. Chem.*, 27, 1909-1915 (1990), to form a compound of the general formula I wherein D is SO₂, B is

15 >NR⁵, R² is H, and R⁴ and R⁵ together form a bond.

f) reacting a compound of the formula V


20



(V)

wherein R¹ and A are defined as above, with a compound of formula VIII

25




(VIII)

30

wherein Y is NH or S, or a suitable salt thereof using procedures described by Kotovskaya S.K. et al., *Khim.-Farm. Zh.*, 13, 54-57 (russ.) (1979) and Topliss J.G. et al., *J. Org. Chem.*, 28, 2313 (1963), to form a compound of the general formula I, wherein D is SO₂, B is >NR⁵, R⁴ and R⁵ together form a bond, and R² and R³ are H.

35

g) reacting in the presence of a base a compound of formula IX



10


or a suitable salt thereof, wherein R¹¹ is R¹ or EtOC(=O), wherein R¹ and A are defined as above, with a compound of formula X

15




wherein R³ is as defined above, to form an adduct which may have either of the two structures XI or XII or be a mixture of the two

20




25



35 either of which by ring-closure, e.g. by treatment with phosgene in a suitable solvent, forms a compound of the general formula I, if R¹¹ is R¹, wherein D is S(=O)₂, B is >NR⁵, R² is H, and R⁴ and R⁵ together form a bond, and a compound of the general formula XIII if R¹¹ is EtOC(=O);


5



10

h) hydrolyzing and subsequently decarboxylating a compound of the general formula XIII

15



20

to form a compound of the general structure I, wherein D is S(=O)₂, B is >NR⁵, R¹ and R² are H, and R⁴ and R⁵ together form a bond, e.g. by heating the starting compound in aqueous base.

25

The starting materials are either known compounds or compounds which may be prepared in analogy with the preparation of known compounds or in analogy with known methods as described by e.g Huang B.-S., et al., J. Med. Chem., 23, 575-7 (1980), Ofitserov V. I. et al., *Khim. Geterotsikl. Soedin.*, 1119-22 (russ.) (1976), Topliss J. G., U.S. 3,641,017 (1972), Kotovskaya S. K. et al., *Khim.-Farm. Zh.*, 13, 54-57 (russ.) (1979), Meyer R. F., *J. Heterocycl. Chem.*, 6, 407-408 (1969) and Hattori M., Yoneda M., and Goto M., *Bull. Chem. Soc. Jap.*, 46, 1890-1 (1973), Williams T.R. and Cram D.J., *J. Org. Chem.*, 38, 20-26 (1973), Barnes A.C., Kennewell P.D. and Taylor J.B., *J. Chem. Soc. Chem. Commun.*, 1973, 776-777, Stoss and Satzinger, *Chem. Ber.*, 109, 2097 (1976), Kresze G., Hatjissaak A., *Phosphorus Sulfur*, 29, 41-47 (1987), Dillard R.D., Yen T.T., Stark P., Pavay D.E., *J. Med. Chem.*, 23, 717-722 (1980).

PHARMACOLOGICAL METHODS

35

The ability of the compounds to interact with potassium channels can be determined by various methods. When patch-clamp techniques (Hamill O.P., Marty A., Neher E., Sakman B. and Sigworth

F.J., *Plügers Arch.*, 391, 85-100 (1981)) are used the ionic current through a single channel of a cell can be recorded.

The activity of the compounds as potassium channel openers can also be measured as relaxation of
5 rat aortas rings according to the following procedure:

A section of rat thoracic aorta between the aortic arch and the diaphragm was dissected out and mounted as ring preparations as described by Taylor P.D. et al , *Brit J. Pharmacol.* 111, 42-48 (1994).

- 10 After a 45 min. equilibration period under a tension of 2 g, the preparations were contracted to achieve 80% of the maximum response using the required concentration of phenylephrine. When the phenylephrine response reached a plateau, potential vasodilatory agents were added cumulatively to the bath in small volumes using half log molar increments at 2 min intervals. Relaxation was expressed as the percentage of the contracted tension. The potency of a compound was expressed as
15 the concentration required to evoke a 50% relaxation of the tissue.

Relaxation of rat aorta rings

Compound	EC50 micro M
1	1.2
20 2	15
16	6.1

- In the pancreatic b-cell the opening of the K_{ATP}-channels can be determined by measuring the subsequent change in the concentration of cytoplasmic free Ca²⁺ concentration according to the
25 method of Arkhammar P. et al . , *J. Biol. Chem.*, 262, 5448-5454 (1987).

⁸⁶Rb⁺ efflux from a β-cell line

- The RIN 5F cell line was grown in RPMI 1640 with Glutamax I, supplemented with 10 % fetal calf serum (from GibcoBRL, Scotland, UK) and maintained in an atmosphere of 5 % CO₂ / 95 % air at 37°C. The cells were detached with a Trypsin-EDTA solution (from GibcoBRL, Scotland, UK), resuspended in medium, added 1 mCi/ml ⁸⁶Rb⁺ and replated into microtiter plates (96 well cluster 3596, sterile, from Costar Corporation, MA, USA) at a density of 50000 cells/well in 100 ml/well, and grown 24 hours before use in assay.
35

The plates were washed 4 times with Ringer buffer (150 mM NaCl, 10 mM Hepes, 3.0 mM KCl, 1.0 mM CaCl₂, 20 mM Sucrose, pH 7.1). Eighty ml Ringer buffer and 1 ml control- or test compound

dissolved in DMSO was added. After incubation 1 h at room temperature with a lid, 50 ml of the supernatant was transferred to PicoPlates (Packard Instrument Company, CT, USA) and 100 ml MicroScint40 (Packard Instrument Company, CT, USA) added. The plates were counted in TopCount (Packard Instrument Company, CT, USA) for 1 min/well at the ^{32}P program.

5

The calculation of EC_{50} and E_{\max} was done by SlideWrite (Advanced Graphics Software, Inc., CA, USA) using a four parameter logistic curve: $y = (a-d)/(1+(x/c)^b)+d$, where a = the activity estimated at concentration zero, b = a slope factor, c = the concentration at the middle of the curve and, d = the activity estimated at infinite concentration. $\text{EC}_{50} = c$ and $E_{\max} = d$, when the curve is turned of at infinite concentrations.

10

Inhibition of Rb-efflux in NIH 3T3 cells

Compound	EC50 micro M
1	2.7
15 16	5.9

20

The compounds according to the invention are effective over a wide dosage range. In general satisfactory results are obtained with dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day. A most preferable dosage is about 5 mg to about 200 mg per day. The exact dosage will depend upon the mode of administration, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.

25

The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.

30

Typical compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols,

35

polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The 5 formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.

The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, 10 emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.

For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.

15 Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.

20 A typical tablet, appropriate for use in this method, may be prepared by conventional tabletting techniques and contains:

Active compound	5.0 mg
Lactosum	67.8 mg Ph.Eur.
Avicel®	31.4 mg
Amberlite®	1.0 mg
Magnesii stearas	0.25 mg Ph.Eur.

30 Due to their high degree of activity, the compounds of the invention may be administered to an animal in need of such treatment, prevention, elimination, alleviation or amelioration of various diseases as mentioned above and especially of diseases of the endocrinological system such as hyperinsulinaemia and diabetes. Such animals include both domestic animals, e.g. household pets, and non-domestic animals such as wildlife. Preferably the animal is a mammal especially a human.

EXAMPLES

The process for preparing compounds of formula I and preparations containing them is further illustrated in the following examples which, however, are not to be construed as limiting.

5

EXAMPLE 16-Chloro-3-(1,2-dimethylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

10 A.

a) Ethyl 5-chloro-2-sulfamoylthiophene-3-carboxylate

A solution of 2-(N-tert-butylsulfamoyl)-5-chlorothiophene-3-carboxylic acid (60.0 g; 0.201 mol) made by the procedure described by B. Unterhalt and S. Moghaddam, Pharmazie 49, 115-117 (1994) in 700 ml of abs. ethanol saturated with hydrogen chloride was heated with stirring at reflux for 17 h. The cooled solution was evaporated to dryness and the residue was purified by trituration with water and dried to give 52.3 g (96%) of the title compound; $^1\text{H-NMR}$ (DMSO- d_6): δ 1.31 (t, J = 7 Hz, 3H, CH_3), 4.32 (q, J = 7 Hz, 2H, CH_2), 7.55 (s, 1H), 7.77 (br. s, 2H, NH_2).

20

b) 5-Chloro-2-sulfamoylthiophene-3-carbohydrazide

Ethyl 5-chloro-2-sulfamoylthiophene-3-carboxylate (50.0 g; 0.185 mol) was added in one portion to 98% hydrazine hydrate (50 ml) with stirring at ambient temperature. The reaction was slightly exothermic. The solution was stirred for 90 min. and concentrated. The residue was crystallised by trituration with 250 ml of water and the mixture was adjusted to pH 2-3 with conc. hydrochloric acid and stirred for 30 min. at 0°C. The product was isolated by filtration, washed with water and dried to give 42.4 g (89%) of the title compound; $^1\text{H-NMR}$ (DMSO- d_6): δ 4.7 (br. s, 2H, NH_2), 7.49 (s, 1H), 7.71 (br. s, 2H, NH_2), 9.94 (br. s, 1H, NH).

30

c) 5-Chloro-2-sulfamoyl-3-thenoyl azide

A solution of sodium nitrite (3.0 g; 43.4 mmol) in 20 ml of water was added dropwise with stirring at 0°C to a solution of 5-chloro-2-sulfamoylthiophene-3-carbohydrazide (10.0 g; 39.1 mmol) in 80 ml of 1M hydrochloric acid and the mixture was stirred for 15 min. The precipitate was isolated by filtration, washed with water and dried to give 9.93 g (96%) of the title compound; $^1\text{H-NMR}$ (DMSO- d_6): δ 7.55 (s, 1H), 7.97 (br. s, 2H, NH_2).

d) 6-Chloro-2,3-dihydro-3-oxo-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

5 5-Chloro-2-sulfamoyl-3-thenoyl azide (7.0 g; 26.2 mmol) was added in portions to 50 ml of refluxing dry toluene during 10 min. The mixture was stirred for 5 min. and cooled on an ice bath. The precipitate was isolated by filtration, washed with toluene and dried to give 5.90 g (94%) of the title compound; m.p. 245-248°C decomp.; ¹H-NMR (DMSO-d₆): δ 6.93 (s, 1H), 11.98 (s, 1H, NH).

e) 6-Chloro-3-(1,2-dimethylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

10 Phosphorus pentoxide (2.84 g; 20 mmol), N,N-dimethylcyclohexylamine (5 ml, 33 mmol) and 1,2-dimethylpropylamine hydrochloride (2.47 g; 20 mmol) were carefully mixed in a three necked flask equipped with mechanical stirring and condenser with drying tube. The mixture was heated on an oil bath at 200°C until a homogeneous mass was obtained. Then 6-chloro-2,3-dihydro-3-oxo-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (1.2 g; 5 mmol) was added and the mixture was stirred at 240°C for 45 min. The mixture was allowed to cool to about 100°C, 150 ml of water was added and stirring was continued at ambient temperature for approximately 1 h. The hydrolysed mixture was filtered and the dark precipitate was washed with water and dissolved in boiling ethanol, treated with charcoal, filtered and finally evaporated to dryness. Flash chromatography (ethyl acetate/silica gel) afforded 105 mg (7%) of the pure title compound; m.p. 216-218°C; ¹H-NMR (DMSO-d₆): δ 0.90 (d, 6H, CH(CH₃)₂), 1.08 (d, 3H, NCHCH₃), 1.75 (m, 1H, CH(CH₃)₂), 3.65 (m, 1H, NHCH), 7.11 (br. s, 2H, 5-H + NH), 10.68 (s, 1H, NH); MS m/e: 307/309 (M⁺).

25 Alternatively, 6-chloro-3-(1,2-dimethylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide could be prepared by the following procedure

B.

a) 3,6-Dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

30 A suspension of 6-chloro-2,3-dihydro-3-oxo-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (10.75 g, 0.045 mol) in phosphorus oxychloride (100 ml) was cooled on an ice bath and dry pyridine (7.3 ml, 0.09 mol) was added dropwise at such a rate that the temperature did not exceed 10°C. The mixture was then heated at 95°-100°C for 16 h, and cooled to room temperature. A yellow precipitate was removed by filtration, and the filtrate was concentrated *in vacuo*. To the residue was added 200 g of ice, and the resulting mixture was stirred for 1 h, and filtered. The isolated solid was dissolved in saturated aqueous sodium hydrogen carbonate (100 ml), and filtered to remove a small amount of insoluble material. After treatment with decolorising charcoal the filtrate was adjusted to pH 2 with 4

M hydrochloric acid and the precipitate that formed was filtered, washed with water and dried to yield 5.55 g (48 %) of the title compound; mp >240°C decomp.

b) 6-Chloro-3-(1,2-dimethylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

5

A solution of 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (0.5 g, 1.94 mmol) in 1,2-dimethylpropylamine (5 ml) was stirred for 48 h at 100°C in a sealed flask. The cooled mixture was concentrated *in vacuo* and the residue was stirred with water (20 ml) followed by adjustment to pH 2 with 4M hydrochloric acid. The initially formed gummy product crystallised by stirring the mixture for about 2 h at 0°C. The precipitate was isolated by filtration, washed with water, and recrystallised from ethyl acetate/methanol followed by drying *in vacuo* at 60°C over night to give 0.43 g (72 %) of the pure title compound.

10

EXAMPLE 2

15

6-Chloro-3-ethylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

20

Phosphorus pentoxide (2.84 g, 20 mmol), N,N-dimethylcyclohexylamine (3 ml, 20 mmol) and ethylamine hydrochloride (1.63 g, 20 mmol) were carefully mixed and heated with stirring on an oil bath at 180°C for 20 min. To the homogeneous mass was added 6-chloro-2,3-dihydro-3-oxo-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (1.2 g, 5 mmol) and the mixture was stirred at 180°C for 5 h. After cooling to ca. 100°C, water (150 ml) was added and the mixture was stirred for 1 h at room temperature. Then the mixture was extracted with ethyl acetate (3 x 100 ml). The organic phase was washed with saturated aqueous sodium hydrogen carbonate, dried and evaporated to dryness. The residue was recrystallised from ethyl acetate/methanol to give 282 mg (21%) of the pure title compound; m.p. 271-274°C; ¹H-NMR (DMSO-d₆): δ 1.11 (t, 3H, CH₃), 3.22 (m, 2H, CH₂), 7.04 (s, 1H, 5-H), 7.3 (br. s, 1H, NH), 11.1 (br. s, 1H, NH); MS m/e: 265/267 (M⁺); (C₇H₈N₃Cl₁O₂S₂) calc. C 31.64 H 3.03 N 15.81, found C 31.57 H 3.12 N 15.63.

25

30

EXAMPLE 3

6-Chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

A.

35

The title compound was made by a similar procedure as described in example 2 except that isopropylamine hydrochloride (1.91 g, 20 mmol) was used as the primary amine. Yield: 150 mg (11%); m.p. 281-283°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 1.15 (d, 6H, CH(CH₃)₂), 3.88 (m, 1H,

CH), 7.08 (s, 1H, 5-H), 7.20 (br. d, 1H, NH), 10.74 (br. s, 1H, NH); MS m/e: 279/281 (M⁺); (C₈H₁₀N₃Cl₁O₂S₂) calc. C 34.35 H 3.60 N 15.02, found C 34.37 H 3.70 N 14.95.

Alternatively, 6-chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide could be

5 prepared by the following procedure

B.

a) 3-Amino-5-chlorothiophene-2-sulfonic acid *tert*-butylamide:

10

A solution of 38.1 g (0.15 mol) of 5-chlorothiophene-2-sulfonic acid *tert*-butylamide in 300 ml of dry tetrahydrofuran was cooled to -70°C, and n-BuLi (190 ml, 1.6 M in hexane) was added, maintaining the temperature < -65°C. After addition, the mixture was allowed to warm to -20°C and stirred at this temperature for 30 min. A solution of *p*-toluenesulfonyl azide (34 g, 0.17 mol) in 100 ml of dry

15

tetrahydrofuran was added, maintaining the temperature at -20°C, and the cooling bath was removed.

After the mixture had reached room temperature, water (100 ml) was added. The organic phase was isolated and the aqueous phase was extracted with toluene (2 x 50 ml). To the combined organic phases was added hexadecyltritylphosphonium bromide (7.62 g, 15 mmol) followed by the dropwise addition of a solution of sodium borohydride (6.58 g, 0.174 mol) in 20 ml of water with

20

stirring and cooling to room temperature. The mixture was stirred over night at room temperature, and water (100 ml) was added. The organic phase was isolated, washed with water (2 x 100 ml), dried, and evaporated to dryness. The oily residue was dissolved in ethyl acetate (150 ml) and washed with 1N sodium hydroxide (6 x 100 ml). The organic phase was dried with sodium sulfate, and evaporated to afford a quantitative yield (40.6 g) of crude title compound as an oil, which was used without further

25

purification in the next step.

b) 3-Amino-5-chlorothiophene-2-sulfonamide hydrochloride

30

3-Amino-5-chlorothiophene-2-sulfonic acid *tert*-butylamide (40.4 g) was heated with stirring at 50°C to 60°C in 200 ml of conc. hydrochloric acid for 2.5 h. The crude product was isolated from the cooled mixture by filtration, dried and purified by trituration with 60 ml of ether to afford 17.8 g (48 %) of the title compound. ¹H-NMR (DMSO-d₆): δ 6.64 (s, 1H), 6.84 (very br., 5H).

c) N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-isopropylthiourea

35

Potassium *tert*-butoxide (0.49 g, 4.4 mmol) was added to a solution of 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride (0.5 g, 2.0 mmol) in dry *N,N*-dimethylformamide (5 ml) with stirring on an

ice bath. After 5 min, isopropyl isothiocyanate (0.26 ml, 2.4 mmol) was added dropwise to the resulting suspension, and the mixture was stirred for 30 min at 0°C. The cooling bath was removed, and stirring was continued at room temperature for 30 min. The solvent was evaporated at <50°C, and the residue was taken up in 25 ml of water, treated with decolorising charcoal, and filtered.

- 5 Acidification of the filtrate with acetic acid to pH 3-4 and filtration afforded 0.50 g (80%) the title compound; mp 142.0-142.5°C decomp., ¹H-NMR (DMSO-d₆): δ 1.12 (d, 6H), 4.25 (m, 1H), 6.48 (br s, 2H), 6.65 (s, 1H), 8.02 (d, 1H), 11.2 (br s, 1H).

d) 6-Chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 10 Phosgene (1.14 ml, 20 % in toluene) was added dropwise to a solution of *N*-(3-amino-5-chloro-2-thienylsulfonyl)-*N'*-isopropylthiourea (0.63 g, 2.0 mmol) and dry triethylamine (0.56 ml, 4.0 mmol) in dry tetrahydrofuran (10 ml) with stirring at 0°C. The mixture was stirred for 1 h at 0°C, and evaporated to dryness. The residue was triturated with water, and the precipitate was isolated by filtration, washed 15 with water and dried affording 0.52 g (93%) of the title compound.

Alternatively 6-chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide could be prepared by the following procedure

- 20 C.
A solution of 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (1.5 g, 5.83 mmol) in isopropylamine (10 ml) was stirred in a Teflon-lined stainless steel pressure bomb at 100°C for 24 h. Excess amine was evaporated, and the residue was stirred in water (25 ml) followed by the addition 25 of 4M hydrochloric acid to pH 2. The mixture was stirred on an ice bath for about 1h to afford 0.99 g (61 %) of the title compound as a crystalline product.

EXAMPLE 4

- 30 (R)-6-Chloro-3-(1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and L- α -methylbenzyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 195-204°C (ethyl acetate), ¹H-NMR (DMSO-d₆): δ 1.46 (d, 3H), 4.95 (m, 1H), 7.1 (s, 1H), 35 7.2-7.45 (m, 5H), 7.78 (br. s, 1H), 10.85 (s, 1H).

EXAMPLE 53-Allylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 5 The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and allyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 217-221°C; ¹H-NMR (DMSO-d₆): δ 3.83 (distorted t, 2H), 5.08-5.27 (m, 2H), 5.75-5.99 (m, 1H), 7.07 (s, 1H), 7.49 (br. t, 1H), 11.1 (s, 1H).

10

EXAMPLE 66-Chloro-3-cyclopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 15 The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and cyclopropyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 272-273°C; ¹H-NMR (DMSO-d₆): δ 0.55 (m, 2H), 0.78 (m, 2H), 2.6 (m, 1H), 7.10 (s, 1H), 7.88 (br. s, 1H), 10.95 (br. s, 1H).

20

EXAMPLE 76-Chloro-3-hexylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 25 The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and n-hexyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 207-209°C; ¹H-NMR (DMSO-d₆): δ 0.87 (distorted t, 3H), 1.28 (m, 6H), 1.51 (m, 2H), 3.17 (q, 2H), 7.05 (s, 1H), 7.30 (br. s, 1H), 11.01 (s, 1H).

EXAMPLE 8

30

6-Chloro-3-tetradecylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and n-tetradecyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 157-158°C; ¹H-NMR (DMSO-d₆): δ 0.85 (distorted t, 3H), 1.25 (m, 22H), 1.50 (m, 2H), 3.19 (q, 2H), 7.05 (s, 1H), 7.26 (br. s, 1H), 10.95 (br. s, 1H).

EXAMPLE 96-Chloro-3-methylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 5 The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and methyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp > 190°C decomp.; ¹H-NMR (DMSO-d₆): δ 2.75 (s, 3H), 7.02 (s, 1H), 7.25 (br, 1H), 11.3 (br s, 1H).

10

EXAMPLE 103-Benzylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 15 The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and benzyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 223-226°C.; ¹H-NMR (DMSO-d₆): δ 4.42 (d, 2H), 7.05 (s, 1H), 7.30 (m, 5H), 7.78 (br t, 1H), 11.22 (br s, 1H).

20

EXAMPLE 116-Chloro-3-octylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 25 The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and n-octyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp >190°C decomp.; ¹H-NMR (DMSO-d₆): δ 0.85 (t, 3H), 1.28 (m, 10H), 1.50 (m, 2H), 3.18 (q, 2H), 7.03 (s, 1H), 7.25 (br, s, 1H), 10.2 (br, s, 1H).

30

EXAMPLE 126-Chloro-3-isobutylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and isobutyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 262-264°C.; ¹H-NMR (DMSO-d₆): δ 0.90 (d, 6H), 2.85 (m, 1H), 3.02 (t, 2H), 7.08 (s, 1H), 7.3 (br, s, 1H), 10.9 (br, s, 1H).

35

EXAMPLE 136-Chloro-3-(4-phenylbutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 5 The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and 4-phenylbutyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 201-205°C; ¹H-NMR (DMSO-d₆): δ 1.55 (m, 4H), 2.6 (t, 2H), 3.2 (q, 2H), 7.04 (s, 1H), 7.1-7.4 (m, 6H), 10.94 (br. s, 1H).

10

EXAMPLE 146-Chloro-3-(1,5-dimethylhexyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 15 The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and 1,5-dimethylhexyl isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 197-199°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 0.85 (d, 6H), 1.12 (d, 3H), 1.1-1.6 (m, 7H), 3.77 (m, 1H), 7.07 (s, 1H), 7.12 (br. s, 1H), 10.72 (br.s, 1H).

20

EXAMPLE 156-Chloro-3-propylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 25 The title compound was prepared from 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide and n-propylamine by a procedure analogous to the procedure described in example 1Bb, except that the mixture was stirred for 16 h at 60°C; mp 258-261°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 0.89 (t, 3H), 1.52 (sext, 2H), 3.15 (q, 2H), 7.05 (s, 1H), 7.29 (br. s, 1H), 10.95 (br. s, 1H).

EXAMPLE 16

30

(R)-6-Chloro-3-(2-hydroxy-1-methylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- The title compound was prepared from 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide and (R)-(-)-2-amino-1-propanol by a procedure analogous to the procedure described in example 1Bb; mp 35 203-204°C (water), ¹H-NMR (DMSO-d₆): δ 1.11 (d, 3H), 3.4 (d, 2H), 3.78 (m, 1H), 4.95 (br. s, 1H), 7.05 (br. s, 1H), 7.09 (s, 1H), 10.8 (br. s, 1H).

EXAMPLE 17(S)-6-Chloro-3-(2-hydroxy-1-methylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 5 The title compound was prepared from 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide and L-alaninol by a procedure analogous to the procedure described in example 1Bb; mp 204-206°C (water). ¹H-NMR (DMSO-d₆): δ 1.11 (d, 3H), 3.4 (d, 2H), 3.78 (m, 1H), 4.95 (br. s, 1H), 7.05 (br. s, 1H), 7.09 (s, 1H), 10.8 (br. s, 1H).

10

EXAMPLE 18(R)-3-sec-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 15 The title compound was prepared from 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide and (R)-(-)-sec-butylamine by a procedure analogous to the procedure described in example 1Bb; mp 215-220°C (water). ¹H-NMR (DMSO-d₆): δ 0.88 (t, 3H), 1.11 (d, 3H), 1.48 (m, 2H), 3.69 (m, 1H), 7.07 (s, 1H), 7.14 (br. s, 1H), 10.75 (br. s, 1H).

20

EXAMPLE 193-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 25 The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and n-butylamino isothiocyanate by a procedure analogous to the procedure described in example 3Bc-d; mp 218-219°C; ¹H-NMR (DMSO-d₆): δ 0.90 (t, 3H), 1.35 (sext, 2H), 1.50 (quint, 2H), 3.18 (q, 2H), 7.02 (s, 1H), 7.25 (br. s, 1H), 10.95 (br.s, 1H).

EXAMPLE 20

30

3-Isopropylamino-7-methyl-4,7-dihydro-pyrazolo[4,3-e][1,2,4]thiadiazine 1,1-dioxidea) 1-Methyl-5-sulfamoylpyrazole-4-carbohydrazide

- 35 Ethyl 1-methyl-5-sulfamoylpyrazole-4-carboxylate (1.0 g), prepared according to Bellemain and Festal, J.Heterocycl.Chem. 1984, 21, 1017, was stirred with 1 ml of hydrazine monohydrate at room temperature for 3 h and then evaporated to dryness. The residue was taken up in 5 ml of water and

extracted with 25 ml of dichloromethane. The aqueous phase was evaporated to give 0.85 g (90%) of the title compound as a slowly crystallizing oil. Trituration with 5 ml of a 2:1 mixture of methanol and ethyl acetate gave a pure product; m.p. 172-173 °C.

5 b) 1-Methyl-4-(azidocarbonyl)pyrazole-5-sulfonamide

A solution of sodium nitrite (0.19 g) in 5 ml of water was added dropwise to a stirred solution of 1-methyl-5-sulfamoylpyrazole-4-carbohydrazide (0.55 g) in 8 ml of 1 M hydrochloric acid at 0°C. The resulting mixture was stirred for 15 min. and then filtered. The filter cake was washed with water and dried in vacuum to give 0.29 g (47%) of the title compound as a crystalline solid. The product was pure according to TLC (ethyl acetate) and was used immediately for the next step.

c) 1-Methyl-4-(ethoxycarbonylamino)pyrazole-5-sulfonamide

15 1-Methyl-4-(azidocarbonyl)pyrazole-5-sulfonamide (0.29 g) was added over 5 min. to 10 ml of abs. ethanol at reflux temperature. The resulting solution was refluxed for 15 min. and then evaporated to give 0.33 g of the title compound as a yellow oil containing a small residue of ethanol. The product was used without purification for the next step.

20 d) N-(4-Ethoxycarbonylamino-1-methyl-5-pyrazolesulfonyl)-N'-isopropylthiourea

A mixture of 1-methyl-4-(ethoxycarbonylamino)pyrazole-5-sulfonamide (0.42 g), potassium carbonate (0.34 g) and isopropyl isothiocyanate (280 µl) in 10 ml of dry acetone was heated at 55 °C for 18 h and then evaporated to dryness. The residue was dissolved in 10 ml of water, and pH was adjusted to 2 by dropwise addition of 4 M hydrochloric acid. The precipitate was filtered off, rinsed with a small amount of water and dried to give 0.38 g (64%) of the title compound; m.p. 141-144 °C.

e) 4-Ethoxycarbonyl-3-isopropylamino-7-methyl-4,7-dihydropyrazolo[4,3-e][1,2,4]thiadiazine 1,1-dioxide

30 To a stirred solution of N-(4-ethoxycarbonylamino-1-methyl-5-pyrazolesulfonyl)-N'-isopropylthiourea (0.37 g) and triethylamine (0.45 ml) in 5 ml of dry THF at 0 °C was added 1.0 ml of a 20% solution of phosgene in toluene. The mixture was stirred at 0 °C for 30 min. and then evaporated to dryness. The residue was triturated with 10 ml of water, filtered off, rinsed on the filter with water and dried to give 35 0.27 g (82%) of the title compound; m.p. 141-145 °C.

f) 3-Isopropylamino-7-methyl-4,7-dihydro-pyrazolo[4,3-e][1,2,4]thiadiazine 1,1-dioxide

- A mixture of 4-ethoxycarbonyl-5-isopropylamino-1-methyl-1,4-dihydro-pyrazolo[4,3-e][1,2,4]thiadiazine 7,7-dioxide (0.23 g) and 2 ml of 2 M aqueous sodium hydroxide was heated at reflux for 2 h. Then the mixture was cooled to room temperature and pH was adjusted to 2 by
5 dropwise addition of 4M hydrochloric acid. After stirring for 15 min. the precipitate was filtered off, rinsed with a small amount of water and dried to give 0.11 g (61%) of the title compound; m.p. 242-243 °C; ¹H-NMR (DMSO-d₆): δ (ppm) 10.25 (s, 1 H, NH), 7.42 (s, 1 H, 3-H), 7.21 (br d, 1 H, NH), 3.98 - 3.75 (m, 4 H, CH and N-CH₃), 1.15 (d, 6 H, CH₃).

10


EXAMPLE 21

- 3-Isopropyl-6-methyl-4H-thiazolo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide
- 15 The title compound may be prepared by a similar procedure as described in example 20 starting with ethyl 2-methyl-5-sulfamoylthiazole-4-carboxylate, which in turn was prepared according to Tamura et al. Chem.Pharm.Bull. 1971, 19, 119.

CLAIMS

5 1. A compound of the general formula I

10



wherein

B represents $>NR^5$ or $>CR^5R^6$, wherein R⁵ and R⁶ independently are hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen; or R⁵ and R⁴ together represent one of the bonds in a double bond between the atoms 2 and 3 of formula I;

D represents -S(=O)₂- or -S(=O)-; or

20

D-B represents -S(=O)(R⁷)=N-

wherein R⁷ is C₁₋₆-alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, acyl, or 25 C₁₋₆-alkoxycarbonyl;

30

R¹ is hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I; or R¹ together with R⁴ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I;

R² is hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen;

35

R³ is R⁸; -OR⁸; -C(=X)R⁸; -NR⁸R⁹; bicycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, oxo, acyl or C₁₋₆-alkoxycarbonyl; or aryl substituted with C₁₋₆-alkyl;

- wherein R⁸ is hydrogen; C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)C₁₋₆-alkyl, the C₃₋₆-cycloalkyl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms; or
- 5 straight or branched C₁₋₁₈-alkyl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkyl, aryl, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, oxo, formyl, acyl, carboxy, C₁₋₆-alkoxycarbonyl, or carbamoyl;

X is O or S;

10


R⁹ is hydrogen; C₁₋₆-alkyl; C₂₋₆-alkenyl; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or

15

R⁸ and R⁹ together with the nitrogen atom form a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted with halogen, C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, nitro, amino, cyano, trifluoromethyl, C₁₋₆-monoalkyl- or dialkylamino, oxo; or

20 R³ is

20



25

wherein n,m,p independently are 0,1,2,3 and R¹⁰ is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen; or

30

R² and R³ together with the nitrogen atom forms a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted with halogen, C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, nitro, amino, cyano, trifluoromethyl, C₁₋₆-monoalkyl- or dialkylamino or oxo;

35

A together with carbon atoms 5 and 6 of formula I represents a 5 or 6 membered heterocyclic system comprising one or more nitrogen-, oxygen- or sulfur atoms, the heterocyclic systems optionally being mono- or polysubstituted with halogen; C₁₋₁₂-alkyl; C₃₋₆-cycloalkyl; hydroxy; C₁₋₆-alkoxy; C₁₋₆-alkoxy-

C₁₋₆-alkyl; nitro; amino; cyano; cyanomethyl; perhalomethyl; C₁₋₆-monoalkyl- or dialkylamino; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; C₁₋₆-alkylcarbonylamino; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamyl; carbamyl- methyl; C₁₋₆-monoalkyl- or dialkylaminocarbonyl; C₁₋₆-monoalkyl- or
5 dialkylaminothiocarbonyl; ureido; C₁₋₆-monoalkyl- or dialkylaminocarbonylamino, thioureido; C₁₋₆-monoalkyl- or dialkylaminothiocarbonyl- amino; C₁₋₆-monoalkyl- or dialkylaminosulfonyl; carboxy; carboxy-C₁₋₆-alkyl; acyl; aryl, arylalkyl, aryloxy, the aryl group optionally being mono- or
10 polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)-C₁₋₆-alkyl the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl;

provided that A together with carbon atoms 5 and 6 of formula I do not form a pyridine ring and that

15 the following compounds 3-aminoimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide and 3-(benzoylamino)imidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide are not included:

or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form.

20

2. A compound according to claim 1, wherein R² is hydrogen or C₁₋₆-alkyl.

3. A compound according to claim 1 or 2 wherein R³ is R⁸, -OR⁸, NR⁸R⁹ or aryl, the aryl groups
optionally being substituted with C₁₋₆-alkyl; wherein

25

R⁸ is hydrogen; C₃₋₆-cycloalkyl; (C₃₋₆-cycloalkyl)C₁₋₆-alkyl; a 3 - 6 membered saturated ring system comprising one, two or three nitrogen-, oxygen- or sulfur atoms; or straight or branched C₁₋₁₆-alkyl
optionally substituted with halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkyl or aryl.

30

R⁹ is hydrogen, C₁₋₆-alkyl or C₃₋₆-cycloalkyl; or

R⁸ and R⁹ together with the nitrogen atom form a 4 - 6 membered ring.

35

4. A compound according to any one of the preceding claims wherein R³ is secondary C₃₋₆-alkyl, tertiary C₄₋₆-alkyl, C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)methyl.


5. A compound according to any one of the preceding claims wherein A together with carbon

ϵ -cycloalkyl; acyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl.

9. A compound according to any one of the claims 1 - 8, wherein the general formula I is

5

10



wherein

R¹ and R⁵ independently are hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or

R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I and R¹ is as defined above; or

20 R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I and R⁵ is as defined above;

D represents -S(=O)₂- or S(=O)-; and

25 A, R² and R³ are as defined above.

10. A compound according to claim 9 wherein R¹ and R⁵ independently are hydrogen or C₁₋₆-alkyl.

30 11. A compound according to claims 9 or 10 wherein R¹ together with R⁴ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I.


12. A compound according to any one of the claims 9 - 11, wherein R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I.

35

13. A compound according to any one of the claims 9 - 12 wherein D is -S(=O)₂.

14. A compound according to any one of the claims 1 - 8 wherein the general formula I is

5



10

wherein

R¹ is hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl
optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or

15

R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of
formula I;

D represents -S(=O)R⁷=

20

wherein R⁷ is C₁₋₆-alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with halogen,
hydroxy, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, acyl or
C₁₋₆-alkoxycarbonyl; and

25

A, R² and R³ are as defined above.

15. A compound according to claim 14 wherein R¹ is hydrogen or C₁₋₆-alkyl.

30


16. A compound according to claim 14 or 15 wherein R¹ together with R⁴ represent one of the
bonds in a double bond between the atoms 3 and 4 of formula I.

17. A compound according to any one of the claims 14 - 16 wherein R⁷ is C₁₋₆-alkyl, phenyl or
pyridyl.

35

18. A compound according to any one of the claims 1 - 8 wherein the general formula I is

46



5

wherein

R^1 , R^5 and R^6 independently are hydrogen; hydroxy; C_{1-6} -alkoxy; or C_{1-6} -alkyl, C_{3-6} -cycloalkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen and R^4 is hydrogen; or

10 R^4 together with R^5 represent one of the bonds in a double bond between the atoms 2 and 3 of formula I and R^1 and R^6 are as defined above; or

R^4 together with R^1 represent one of the bonds in a double bond between the atoms 3 and 4 of formula I and R^5 and R^6 are as defined above;

15

D represents $-S(=O)_2-$ or $-S(=O)-$; and

A, R^2 , R^3 are as defined above.

20 19. A compound according to claim 18 wherein R^1 , R^5 and R^6 independently are hydrogen or C_{1-6} -alkyl.

20. A compound according to claim 18 or 19 wherein R^1 together with R^4 represent one of the bonds in a double bond between the atoms 3 and 4 of formula I.

25

21. A compound according to any one of the claims 18 - 20 wherein R^4 together with R^5 represent one of the bonds in a double bond between the atoms 2 and 3 of formula I.

22. A compound according to any one of the claims 18 - 21 wherein D is $-S(=O)_2-$.

30

23. A compound selected from the following:

6-Chloro-3-(1,2-dimethylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

6-Chloro-3-ethylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

35 6-Chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

(R)-6-Chloro-3-(1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;


3-Allylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;

- 6-Chloro-3-cyclopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 6-Chloro-3-hexylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 6-Chloro-3-tetradecylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 6-Chloro-3-methylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 5 3-Benzylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 6-Chloro-3-octylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 6-Chloro-3-isobutylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 6-Chloro-3-(4-phenylbutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 6-Chloro-3-(1,5-dimethylhexyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 10 6-Chloro-3-propylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 (R)-6-Chloro-3-(2-hydroxy-1-methylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 (S)-6-Chloro-3-(2-hydroxy-1-methylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 (R)-3-sec-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 3-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide;
 15 3-Isopropylamino-7-methyl-4,7-dihydro-pyrazolo[4,3-e][1,2,4]thiadiazine 1,1-dioxide.

24. Compounds according to any one of the preceding claims which acts as openers of the K_{ATP} -regulated potassium channels.

- 20 25. A method of preparing a compound of formula I, characterized in
 a) reacting a compound of formula II:

25



(II)

30

wherein A, B, D, R¹ and R⁴ are as defined above and Z is a leaving group such as alkoxy, alkylthio, halogen, preferentially chloro, bromo, iodo, trimethylamino, or methylsulfonyl with a compound of formula III:

35



(III)

wherein R² and R³ are defined above to form a compound of the general formula I;

b) reacting a compound of formula IV:

5



10

wherein R¹ is hydrogen and A, B, D and X are as defined above, or B is NH and R¹, A, D and X are as defined above, with the compound of formula III, or a suitable salt thereof in the presence of P₂O₅ and a high boiling tertiary amine or a suitable salt thereof, to form a compound of the general formula

15

I;

c) reacting a compound of the formula IV:

20



25

wherein R¹ is hydrogen and A, B, D and X are as defined above or B is NH and R¹, A, D and X are as defined above, with a compound of the formula III, or a suitable salt thereof in the presence of titanium tetrachloride and a solvent with which it may form a complex, like e.g. tetrahydrofuran, or a mixture of toluene and anisole, to form a compound of the general formula I;

30

d) reacting a compound of formula V

35



wherein R¹ and A are as defined above, with a compound of formula VI




(VI)

- 5 wherein R³ is as defined above, to form a compound of the general formula I wherein D is SO₂, B is >NR⁵, R² is H, and R⁴ and R⁵ together form a bond;

e) reacting a compound of the formula V

10



(V)

- 15 wherein R¹ and A are as defined above, with a compound of formula VII




(VII)

- 20 wherein R³ is as defined, to form a compound of the general formula I wherein D is SO₂, B is >NR⁵, R² is H, and R⁴ and R⁵ together form a bond;


f) reacting a compound of the formula V

25



(V)

- 30 wherein R¹ and A are defined as above, with a compound of formula VIII



(VIII)

35

wherein Y is NH or S, or a suitable salt thereof, to form a compound of the general formula I, wherein

D is SO_2 , B is $>\text{NR}^5$, R^4 and R^5 together form a bond, and R^2 and R^3 are H;

g) reacting in the presence of a base a compound of formula IX

5

10



10



or a suitable salt thereof, wherein R^{11} is R^1 or $\text{EtOC}(=\text{O})$, wherein R^1 and A are defined as above, with
15 a compound of formula X



20


wherein R^3 is as defined above, to form an adduct which may have either of the two structures XI or
XII or be a mixture of the two

25




either of which by ring-closure, e.g. by treatment with phosgene in a suitable solvent, forms a
35 compound of the general formula I, if R^{11} is R^1 , wherein D is $\text{S}(=\text{O})_2$, B is $>\text{NR}^5$, R^2 is H, and R^4 and
 R^5 together form a bond, and a compound of the general formula XIII if R^{11} is $\text{EtOC}(=\text{O})$;

5



10

15



to form a compound of the general formula I, wherein D is $S(=O)_2$, B is $>NR^5$, R^1 and R^2 are H, and
20 R^4 and R^5 together form a bond, e.g. by heating the starting compound in aqueous base.

26. A pharmaceutical composition comprising a compound according to any of the claim 1 - 24 or a or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or
25 any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or more pharmaceutically acceptable carriers or diluents.

27. A pharmaceutical composition for use in the treatment of diseases of the endocrinological system such as hyperinsulinaemia and diabetes comprising a compound according to any of the claims 1 - 24 or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or more pharmaceutically acceptable carriers or diluents.

28. The pharmaceutical composition according to claim 26 or 27 in the form of an oral dosage unit or parenteral dosage unit.

29. A pharmaceutical composition according to claim 26 or 27 wherein said compound is

administered as a dose in a range from about 0.05 to 1000, preferably from about 0.1 to 500 and especially in the range from 50 to 200 mg per day.

30. A compound according to any one of the claims 1 - 24 or a pharmaceutically acceptable salt

5 thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for therapeutical use.

31. A compund according to any one of the claims 1 - 24 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical

10 isomers, including a racemic mixture, or any tautomeric form for therapeutical use in the treatment or prevention of diseases of the endocrinological system, such as hyperinsulinaemia and diabetes.

32. The use of a compound according to any one of the claims 1 - 24 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or

15 mixture of optical isomers, including a racemic mixture, or any tautomeric form as a medicament.

33. The use of a compound according to any of the claims 1 - 24 for preparing a medicament.

34. The use of a compound according to any one of the claims 1 - 24 or a pharmaceutically

20 acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for the preparation of a medicament for the treatment or prevention of diseases of the endocrinological system, such as hyperinsulinaemia and diabetes.

25 35. A method of treating or preventing diseases of the endocrinological system, such as hyperinsulinaemia and diabetes in a subject in need thereof comprising administering an effective amount of a compound according to any of the claims 1 - 24 to said subject.

36. A process for the manufacture of a medicament, particular to be used in the treatment or

30 prevention of diseases of the endocrinological system, such as hyperinsulinaemia and diabetes which process comprising bringing a compound of formula I according to any of the claims 1 - 24 or a pharmaceutically acceptable salt thereof into a galenic dosage form.

37. Any novel feature or combination of features as described herein.

INTERNATIONAL SEARCH REPORT

International application No. PCT/DK 97/00019
--

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: C07D 513/04, A61K 31/54 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: C07D, A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CA, WPI		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. Med. Chem., Volume 23, 1980, Bao-Shan Huang et al, "Synthesis and Properties of the Sulfonyl Analogues of 4(5)-Aminoimidazole-5(4)-carboxamide, 4(5)-(Formylamino)imidazole-5(4)-carboxamide, Guanine, and Xanthine" page 575 - page 577 --	1-31,36,37
X	J. Med. Chem., Volume 36, 1993, (Bernard Pirotte et al), 3-(Alkylamino)-4H-pyrido(4,3-e)-1,2,4-thiadiazine 1,1-Dioxides as, "Powerful Inhibitors of Insulin Release from Rat Pancreatic B-Cells: A New Class of Potassium Channel Openers?" page 3211 - page 3213 --	1-31,33,34, 36,37
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report	
14 April 1997	26-04-1997	
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Gerd Strandell Telephone No. +46 8 782 25 00	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00019

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Biochemical Pharmacology, Volume 47, No 8, 1994, B. Pirotte et al, "A Pyridothiadiazine (BPDZ 44) as a new and potent activator of ATP-Sensitive K+Channels" page 1381 - page 1386 --	1-31,33,34, 36,37
X	EP 0618209 A1 (ADIR ET COMPAGNIE), 5 October 1994 (05.10.94) --	1-31,33,34, 36,37
X	GB 1368948 A (MANUFACTURE DE PRODUITS PHARMACEUTIQUES A. CHRISTIAENS S.A.), 2 October 1974 (02.10.74) --	1-31,36,37
X	Metabolism, Volume 40, No 8, 1991, William D. Vlahos et al, "Diabetes Prevention in BB Rats by Inhibition of Endogenous Insulin Secretion" page 825 - page 829 -----	1-31,33,34, 36,37

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00019

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 32, 35
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

04/03/97

International application No.
PCT/DK 97/00019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0618209 A1	05/10/94	AU 673893 B AU 5904894 A CA 2119853 A FR 2703051 A,B JP 2513989 B JP 7002872 A NZ 260186 A US 5459138 A ZA 9402131 A	28/11/96 29/09/94 27/09/94 30/09/94 10/07/96 06/01/95 26/07/95 17/10/95 05/04/95
GB 1368948 A	02/10/74	AT 321301 B AT 324341 B BE 775166 A CA 1008859 A DE 2155483 A FR 2113927 A,B LU 64237 A NL 7115510 A US 3819639 A US 3980652 A US 3991057 A US 4002629 A	25/03/75 25/08/75 10/05/72 19/04/77 08/06/72 30/06/72 29/05/72 15/05/72 25/06/74 14/09/76 09/11/76 11/01/77

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.